Celldex Therapeutics, Inc. (CLDX) Stock

Celldex Therapeutics, Inc. (CLDX) is a Healthcare stock trading at $32.42 (as of 2026-06-18), with a market capitalization of $2.47B and a trailing P/E of -7.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Celldex Therapeutics, Inc. is a biopharmaceutical company developing therapeutic monoclonal and bispecific antibodies for inflammatory diseases and cancer. Its clinical programs include CDX-0159 (KIT-targeted monoclonal antibody), CDX-1140 (CD40 agonist antibody), and CDX-527 (bispecific antibody combining PD-L1/PD-1 pathway blockade with CD27 costimulation), intended for treating patients.

Valuation — source: SEC EDGAR (first-party)
Price	$32.42
Market Cap	$2.47B
P/E Ratio	-7.3
EV / EBITDA	-7.9
Price / Book	5.38
Price / Sales	2837.51
DCF Value (model)	$-54.21
DCF Upside vs Price	-267.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$1.54M
Net Margin	-16748.0%
Return on Equity	-62.2%
Current Ratio	8.92
Revenue Growth (YoY)	-78.0%
EPS Growth (YoY)	59.2%
FCF Growth (YoY)	33.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	18.22 (safe)

Valuation vs Sector & Industry
Stock P/E	-7.3
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-134.9%
vs Industry	-142.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	WELLINGTON MANAGEMENT GROUP LLP ($271.54M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Anthony S. Marucci
Employees	186
Country	US
IPO Date	1986-05-15

Related Companies (Business model: Clinical Labs / CRO Services; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.